MaxCyte (MXCT)
Supplies ExPERT electroporation tools, consumables, licenses, and gene-editing assay services.
Something off on this page? Send us feedback.
Sells ExPERT instruments, Processing Assemblies, consumables, licenses, and assay services for cell therapy, bioprocessing, and research customers. Revenue comes through product sales, research and clinical licenses, and Strategic Platform License milestones within one cell-engineering technology segment.
Built on proprietary Flow Electroporation, the ExPERT platform spans DTx, ATx, STx, GTx, and VLx instruments, plus Processing Assemblies, electroporation buffers, software protocols, and accessories for cell-therapy, bioprocessing, drug-discovery, and research workflows.
Revenue comes from product sales, research and clinical license fees, Strategic Platform License program milestones, and SeQure gene-editing assay services. The business reports one segment, cell engineering technology, and works with biopharmaceutical customers that need scalable non-viral delivery.
Execution depends on converting platform use into recurring consumables, licenses, and milestone-linked programs. Customer development timelines, regulatory-reference support, and competition from larger life-science tool providers shape adoption.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2025 | BTIG | Downgrade | ||
| Aug 7, 2025 | William Blair | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $105.7M · Total debt $17.3M · Total assets $184.7M · Shareholders' equity $158.8M
- Revenue
- $7.3M
- Operating income
- −$10.2M
- Net income
- −$8.9M
No dividends on record.
| Institutions | ≈ 61.45% | 63.42M shares | |
|---|---|---|---|
| 125 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.28% | 2.35M shares | |
| 13 holders · as of Jun 22, 2026 | |||
| Other | ≈ 36.27% | 37.43M shares | |
| remainder | |||
103.21M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Capricorn Fund Managers LtdInstitution | 7.95% | 8.20M | as of Jun 30, 2026 |
Vitruvian Partners LLPInstitution | 4.89% | 5.04M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.91% | 4.03M | as of Jun 30, 2026 |
Morgan StanleyInstitution | 3.58% | 3.69M | as of Jun 30, 2026 |
Mudita Advisors LLPInstitution | 3.27% | 3.37M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 17, 2026 | Douglas J. Swirsky | officer: CHIEF FINANCIAL OFFICER | −10,142 | $0.8150 |
- Thermo Fisher Scientific
Scaled electroporation and cell-therapy workflow rival
- Bio-Rad Laboratories
Research electroporation systems and buffers for difficult cells
- Harvard Bioscience
BTX lab electroporation and electrofusion tools
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MaxCyte | $1.22 | +0.20% | $130.7M | — | — | 4.2 | −14.5% |
| Thermo Fisher Scientific | $662.07 | +0.50% | $244.81B | 35.4 | 25.2 | 5.3 | +10.5% |
| Bio-Rad Laboratories | $381.37 | +1.07% | $10.16B | 45.7 | 37.0 | 3.9 | −0.1% |
| Harvard Bioscience | $8.02 | +0.19% | $36.1M | — | 44.5 | 0.4 | +11.1% |
| Median | 40.6 | 37.0 | 3.9 | +10.5% |